Health Care/Hospital

Laekna, Inc. (2105.HK) Announces Interim Results 2023

* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recurrent ovarian cancer (PROFECTOR-II), the patients were fully enrolled and the topline data is expected in the late fourth quarter of 2023 * For the Phase Ib/III trial of Afuresertib + Fulvestrant ...

2023-08-25 08:00 3488

Ping An Health announces 2023 interim results

Managed care business delivers robust performance  Market leadership in corporate health management drives loss narrowing by 47.2% HONG KONG and SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or "Ping An Health", Stock Code: 1833.H...

2023-08-24 21:00 4273

Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the New Drug Application (NDA) for its...

2023-08-24 20:00 1684

Zhongchao Inc. Announces Serving over 10,000 Breast Cancer Patients with Its Comprehensive Disease Management

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced it has achieved a milestone of serving over 10,000 breast cancer ...

2023-08-24 20:00 1782

111, Inc. Announces Second Quarter 2023 Unaudited Financial Results

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...

2023-08-24 14:00 3156

PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor

TOKYO, Aug. 23, 2023 /PRNewswire/ -- PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-de...

2023-08-24 09:51 1595

Samsung Biologics appoints new leadership to oversee quality and regulatory affairs

- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation. INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract d...

2023-08-24 07:59 1698

Jin Medical International Limited (NASDAQ: ZJYL) Announces Financial Results for Six Months Ended March 31, 2023

CHANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), aCayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced its financial results fo...

2023-08-24 04:15 2929

Complete Genomics Garners the Prestigious 2023 R&D 100 Awards for Cutting-Edge Innovation

SAN JOSE, Calif., Aug. 23, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today proudly received the honor of the R&D 100 Awards from R&D World Magazine, often referred to as the "Oscars of Innovation". Widely recognized in industry, government, and academ...

2023-08-23 23:00 1508

CHINA LIFE INSURANCE COMPANY LIMITED ANNOUNCES 2023 INTERIM RESULTS (H SHARES)

HONG KONG, Aug. 23, 2023 /PRNewswire/ -- China Life Insurance Company Limited (SSE: 601628, SEHK: 2628) announces the unaudited consolidated results of the Company (China Life Insurance Company Limited and its subsidiaries) for the six months ended30 June 2023 (the "Reporting Period") prepared un...

2023-08-23 20:34 3601

Food Science, which developed the world's first hangover drink with the protein of blowfish, launches the fruit-flavored carbonated drink 'VTalk Ade'

* The company was selected as a beneficiary of early-stage technology commercialization investment by Korea Development Bank SEOUL, South Korea, Aug. 23, 2023 /PRNewswire/ -- Food Science, selected by the Ministry of SMEs and Startups as one of 30 companies to participate in this year's Social ...

2023-08-23 20:00 897

Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations

* Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first Chinese Innovative drug approved for NSCLC Patients with EGFR Exon20ins * Approval based on the results of primary endpoint from WU-KONG6 study, which demonstrated a superior confirmed objective re...

2023-08-23 19:21 935

Waterdrop Inc. to Report Second Quarter 2023 Financial Results on September 7, 2023

BEIJING, Aug. 23, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform d...

2023-08-23 18:06 2485

ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor. Dr. Kaufman's expertise in scientific research and clinical development, especially in the areas of oncolytic virus and immunotherapy, will greatly enhance ImmVira's re...

2023-08-23 10:51 1747

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH) – a global innovative pharmaceutical company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases – today release...

2023-08-22 20:58 2226

Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "Sanyou" hereafter) and Sinorda Biomedicine (referred to as " Sinorda " hereafter) have officially signed a strategic cooperation agreement to advance the innovative bispecific antibody drug pro...

2023-08-22 20:00 1803

CARsgen Announced 2023 Interim Results

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights * Collaboration agr...

2023-08-22 19:30 3337

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

SUZHOU, China, Aug. 22, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase...

2023-08-22 17:13 1560

Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model

SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antib...

2023-08-22 08:59 1472

Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment - to be presented at WCLC 2023

- A collaborative study demonstrates that AI analysis of Tertiary Lymphoid Structures (TLS) in tumors can predict treatment response in non-small cell lung cancer patients SEOUL, South Korea, Aug. 21, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for canc...

2023-08-21 21:00 2095
1 ... 78798081828384 ... 277

Week's Top Stories